Fexofenadine_product_DataBase

Bioactivity	Fexofenadine (MDL-16455) is an orally active and nonsedative H1 receptor antagonist. Fexofenadine can be used in allergic rhinitis and chronic idiopathic urticarial research[1][2][3].
Invitro	Fexofenadine (1-100 µM; 1 h) inhibits the expression of IL-6 protein in nasal fibroblasts in a dose-dependent manner[2].Fexofenadine (1-100 µM; 1 h) blocks phosphorylated p38 activation in histamine-induced nasal fibroblasts, but shows no effect on either pERK or pJNK[2]. Western Blot Analysis[2] Cell Line:
In Vivo	Fexofenadine hydrochloride (oral administration; 5-20 mg/kg; once daily; 3 w) suppresses both eosinophilia and systemic anaphylaxis in C57BL/6 mice infected with T. spiralis[1]. Animal Model:
Name	Fexofenadine
CAS	83799-24-0
Formula	C32H39NO4
Molar Mass	501.66
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Watanabe N, et al. The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis. Int Immunopharmacol. 2004 Mar;4(3):367-75. [2]. Park IH, et al. Histamine Promotes the Release of Interleukin-6 via the H1R/p38 and NF-κB Pathways in Nasal Fibroblasts. Allergy Asthma Immunol Res. 2014 Nov;6(6):567-72. [3]. Ming X, et al. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm. 2011 Oct 3;8(5):1677-86.

PeptideDB